How is polycythemia rubra vera diagnosed in Canada?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnosis of Polycythemia Vera in Canada

In Canada, diagnose polycythemia vera using the 2008 WHO revised criteria, which require both major criteria (hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women, AND presence of JAK2 V617F or JAK2 exon 12 mutation) plus one minor criterion, OR the first major criterion plus two minor criteria. 1

Diagnostic Algorithm

Step 1: Confirm Elevated Hemoglobin/Hematocrit (Major Criterion 1)

The hemoglobin thresholds are:

  • Men: ≥18.5 g/dL
  • Women: ≥16.5 g/dL

Alternative criteria include:

  • Hemoglobin/hematocrit at 99th percentile for age, sex, and altitude
  • Hemoglobin ≥17 g/dL in men or ≥15 g/dL in women with documented sustained increase of ≥2 g/dL from baseline (not due to iron correction)
  • Red cell mass >25% above mean normal predicted value (though measurement is not required) 1

Critical pitfall: Do not diagnose PV based on hematocrit alone without excluding secondary causes and confirming clonality.

Step 2: Test for JAK2 Mutations (Major Criterion 2)

Order JAK2 V617F mutation testing immediately. This mutation is present in >90% of PV cases 1.

If JAK2 V617F is negative, test for JAK2 exon 12 mutations, which account for most remaining cases 1.

Key point: The presence of JAK2 mutation confirms clonality and essentially secures the diagnosis when combined with elevated hemoglobin and one minor criterion.

Step 3: Evaluate Minor Criteria (Need 1 if Both Major Criteria Met, or 2 if Only First Major Criterion Met)

The three minor criteria are:

  1. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation 1

  2. Serum erythropoietin level below the reference range for normal 1

  3. Endogenous erythroid colony formation in vitro 1

Practical approach: If both major criteria are met (elevated hemoglobin + JAK2 mutation), you only need ONE minor criterion. The most practical is obtaining a low serum erythropoietin level, which is present in the majority of PV patients and helps exclude secondary causes 1.

Essential Exclusions Before Diagnosis

Before confirming PV, you must exclude:

  • Secondary erythrocytosis: Check oxygen saturation, assess for chronic hypoxia, renal pathology (renal ultrasound if indicated), hepatic pathology, and erythropoietin-secreting tumors 2, 3
  • Relative polycythemia: Ensure this is true erythrocytosis, not plasma volume contraction 4
  • Other myeloid neoplasms: The patient should not meet WHO criteria for CML (BCR-ABL1 negative), MDS, or other myeloproliferative neoplasms 1

When to Perform Bone Marrow Biopsy

Bone marrow biopsy is not always required if both major criteria are met and one minor criterion (like low erythropoietin) is present. However, consider bone marrow biopsy when:

  • JAK2 mutation is negative (to look for characteristic morphology and exclude other diagnoses)
  • Diagnostic uncertainty exists
  • Atypical features are present
  • Confirmation is needed for medico-legal or treatment planning purposes 2, 3

The characteristic bone marrow findings include hypercellularity, panmyelosis, and marked megakaryocyte dyspoiesis 2.

Common Diagnostic Pitfalls

  1. Missing masked PV: The 2008 WHO revision lowered hemoglobin thresholds specifically to capture cases that would have been missed with older criteria. Don't dismiss borderline elevations if JAK2 is positive 2.

  2. Relying solely on hematocrit: Always confirm with hemoglobin levels and exclude secondary causes 3.

  3. Ignoring accompanying cytopenias: Look for leukocytosis and thrombocytosis, which support the diagnosis. If polycythemia is isolated, prioritize excluding secondary causes first 4.

  4. Not testing for JAK2 exon 12 mutations: If JAK2 V617F is negative but clinical suspicion remains high, test for exon 12 mutations 1.

Clinical Context

While the diagnostic criteria are standardized internationally through WHO guidelines, a Canadian study demonstrated that 41.7% of patients did not receive guideline-concordant therapy, and non-adherence to treatment guidelines was independently associated with increased mortality 5. This underscores the importance of accurate diagnosis using these established criteria to ensure appropriate risk stratification and treatment.

The diagnosis integrates clinical findings (splenomegaly, thrombotic history), laboratory parameters (hemoglobin, JAK2 status, erythropoietin), and when needed, bone marrow morphology 2, 6. Normal oxygen saturation confirms the primary nature of the disease 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.